Vaccine may be approved early for high-risk groups, signs given by the central government; Health Minister's trust - Vaccine will be ready before March

Posted on 14th Sep 2020 by rohit kumar

Amid increasing cases of coronaviruses, the central government has indicated that the corona vaccine may be approved early for high-risk groups, ie elderly and frontline health workers. Till now no date has been fixed for the release of the vaccine, yet Health Minister Harsh Vardhan has expressed hope that the vaccine will be ready before March next year. At the same time, American company Pfizer has claimed that its vaccine will come in the US market before December this year. You also know what developments have taken place worldwide on the vaccine that is waiting to control the corona.

 

India can also follow the path of Russia and China

 

Union Health Minister Harsh Vardhan said in a Sunday interaction program on social media that the government can soon approve the vaccine for high-risk groups i.e. elderly and frontline health workers. Efforts are being made to persuade everyone on this.

Harshavardhan's talks indicate that on the lines of Russia and China, the vaccine can be released in India as soon as possible for high-risk groups. Russia has given emergency approval to its SPUTNIK V and China to three of its vaccines.

 

There are three vaccine trials in India. Bharat Biotech and ICMR are developing covaxin. Ahmedabad-based company Zydus Cadila has vaccine phase-2 trials. Pune's Serum Institute of India is doing Phase-2 and Phase-3 trials of Kovyshield of Oxford / AstraZeneca.

It can take four-five years to reach vaccines worldwide

 

CEO of the world's largest vaccine manufacturing company, Serum Institute, Adar Poonawala said in an interview that the vaccine will not be available to everyone worldwide by the end of 2024. He said that it would take four-five years to deliver the vaccine everywhere in every country.

 

Poonawala told the Financial Times that the company has partnered with five companies, including AstraZeneca and Novavax. Preparations are on to make one billion doses. Half of this will be available in India. The company is also preparing to partner with Gamalaya Research Institute of Russia to manufacture SPUTNIK V. Trials of the Oxford / AstraZeneca vaccine were stopped in the UK after a person became ill. But the good thing is that vaccine trials are starting again in Britain. The company has got permission for this. Serum Institute of India is currently awaiting approval from drug regulators in India to resume trials.

 

Serum Institute was issued a show-cause notice by the drug regulator. Serum Institute has responded to this. Soon, KoviShield's stalled trials could gain momentum in India as well. However, at present no formal statement has come in this regard.

 

Pfizer CEO said that vaccine will be available to Americans this year

 

Phase-3 trials are underway in the United States of the vaccine being developed by American company Pfizer and German company Biotech. The company claims to have stepped up efforts to make the vaccine available in the US market this year.

 

Pfizer CEO Albert Baurla told CBS TV Network that we have started manufacturing. We have already made hundreds of doses. If the results of our study on trials are good, then we will not take any time to get into the market.

 

Pfizer had earlier said that by October it would be known whether its vaccine was safe and effective. Baurla repeated the same thing in his interview. He said that there is a 60% chance that by October the company will know how effective the vaccine is.

 

WHO Says Vaccine Landscape…

 

180 vaccines are currently being developed all over the world.

 

35 vaccines are undergoing clinical trials.

 

9 vaccines are in Phase-3 ie final round trials. There are also four vaccines being developed in China.

 

145 vaccines are in the phase of pre-clinical trials. That is, their evaluation is still going on in the labs.